News

Filter

Current filters:

None

Popular Filters

7810 to 7834 of 8849 results

Biotech predictions for 2012 from sector specialist Steven Burrill

03-01-2012

As 2011 drew to a close, Steven Burrill, chief executive of global life sciences financial services firm…

BiotechnologyFinancialMergers & AcquisitionsNorth AmericaPharmaceuticalRegulation

Expanded use for Pfizer’s Prevnar 13

03-01-2012

Following a previous US Food and Drug Administration advisory panel recommendation (The Pharma Letter…

North AmericaPfizerPharmaceuticalPrevnarRegulationVaccines

Takeda ends Daxas co-promotion with MSD; Actos law suits

03-01-2012

Japan’s largest drugmaker, Takeda Pharmaceuticals (TYO: 4502) says that it has reached a mutual…

ActosDaxasDiabetesLegalLicensingMerck & CoNycomedPharmaceuticalRespiratory and PulmonaryTakeda Pharmaceuticals

Knighthood for GlaxoSmithKline’s Andrew Witty; Teva succession plan

03-01-2012

Andrew Witty, chief executive of UK drug giant GlaxoSmithKline (LSE: GSK) has been awarded a Knighthood…

GenericsGlaxoSmithKlineManagementPharmaceuticalTeva Pharmaceutical Industries

Turkey’s AiFD highlights pharma industry woes

03-01-2012

Turkey’s Association of Research-Based Pharmaceutical Companies (AİFD) has issued a public…

EuropePharmaceuticalPoliticsPricing

Emergent considers options as Abbott ends drug R&D collaboration

30-12-2011

Shares of USA-based Emergent BioSolutions (NYSE: EBS) saw its shares fall 4% to $16.53 after the company…

Abbott LaboratoriesEmergent BioSolutionsLicensingOncologyPharmaceuticalResearch

Alexion to buy Enobia Pharma for potential $1 billion

30-12-2011

US drugmaker Alexion Pharmaceuticals (Nasdaq: ALXN) has reached agreement to acquire privately held Canadian…

Alexion Pharmaceuticalsasfotase alfaEnobia PharmaMergers & AcquisitionsPharmaceuticalRare diseases

Apricus Biosciences closes Topotarget USA acquisition

30-12-2011

Apricus Biosciences (Nasdaq: APRI) has closed its previously-announced acquisition of Topotarget USA,…

Apricus BioscienceMergers & AcquisitionsOncologyPharmaceuticalTopotargetTotect

Spanish pharma sales down 3.1% in October

30-12-2011

Data from Spain’s Ministry of Health, Social Policy and Equality shows that, in October 2011, public…

EuropeGenericsMarkets & MarketingPharmaceuticalPricingResearch

UCB and Immunomedics amend epratuzumab accord

29-12-2011

New Jersey, USA-based Immunomedics (Nasdaq: IMMU) and Belgian drugmaker UCB (Euronext Brussels: UCB)…

epratuzumabImmunologicalsImmunomedicsLicensingPharmaceuticalRare diseasesUCB

Australia’s Pharma industry economic impact up by A$1 billion

29-12-2011

The Australian pharmaceutical industry’s contribution to the economy grew by an estimated A$1 billion…

Asia-PacificMarkets & MarketingPharmaceuticalResearch

Baxter taps Momenta expertise on biosimilars

28-12-2011

In another move to capitalize on the anticipated flood of biosimilars coming to the market, as blockbuster…

Baxter InternationalBiotechnologyGenericsLicensingMomenta PharmaceuticalsResearch

Karo Bio skyrockets on deal with Pfizer

28-12-2011

Sweden’s Karo Bio (STO: KARO) saw its shares rocket 80% to 1.67 Swedish ronor on December 24, after…

Anti-Arthritics/RheumaticsImmunologicalsKaro BioLicensingNeurologicalPfizerPharmaceuticalResearch

ViroPharma buys option to acquire Meritage Pharma

28-12-2011

ViroPharma (Nasdaq: VPHM) has entered into an exclusive option to acquire fellow USA based Meritage Pharma,…

BudesonideMergers & AcquisitionsMeritage PharmaPharmaceuticalRare diseasesResearchViroPharma

Bristol-Myer’s brivanib disappoints in Ph III study

28-12-2011

US drug major Bristol-Myers Squibb (NYSE: BMY) has revealed disappointing results of a Phase III trial…

Bristol-Myers SquibbbrivanibOncologyPharmaceuticalResearch

Eisai re-submits perampanel NDA; FDA accepts Gilead’s Quad

28-12-2011

Japanese drug major Eisai (TYO: 4523) says that it has re-submitted the New Drug Application (NDA) for…

Anti-viralsEisaiGilead SciencesNeurologicalperampanelPharmaceuticalQuadRegulation

Exelixis and Sanofi terminate $1 billion cancer deal

23-12-2011

US biotechnology firm Exelixis (Nasdaq: EXEL) says its oncology deal with French drug Major Sanofi (Euronext:…

BiotechnologyExelixisLicensingOncologyPharmaceuticalResearchSanofi

EMA reviewing Novartis aliskiren-containing drugs

23-12-2011

The European Medicines Agency is reviewing aliskiren-containing medicines, approved for the treatment…

Aliskiren TabletsCardio-vascularEuropeNovartisPharmaceuticalRasilezRegulationTekturna

Vivus findings show greater risk of birth defects with Qnexa ingredient

23-12-2011

USA-based drug developer Vivus (Nasdaq: VVUS) has released top-line preliminary results from its retrospective…

MetabolicsNorth AmericaPharmaceuticalQnexaRegulationResearchtopiramateVivus

Merck gains expanded Isentress indication; lowers price of drug for ADAps

23-12-2011

In two pieces of HIV/AIDS-related news for US drugs giant Merck & Co (NYSE: MRK), the company’s…

Anti-viralsIsentressMerck & CoNorth AmericaPharmaceuticalPricingRegulation

Lundbeck divests three branded injectables to Akorn

23-12-2011

Danish CNS drug specialist Lundbeck (LUND: DC) says it has entered into an agreement with USA-based niche…

AkornCogentinDiurilGenericsLundbeckMergers & AcquisitionsNembutalNeurologicalNorth AmericaPharmaceutical

7810 to 7834 of 8849 results

Back to top